

TSW
S

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Iris PECKER et al



Serial No.: 10/676,079

Filed: 02-Oct-2003

For: HEPARANASE SPECIFIC MOLECULAR PROBES AND THEIR USE IN RESEARCH AND MEDICAL APPLICATIONS

Examiner: DIBRINO, MARIANNE NMN

§§§§§
Group Art Unit: 1644
§§§§§
Attorney
Docket: 26871
§§§§§

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Supplemental Information Disclosure Statement is being filed subsequent to an Office Action being mailed and a late fee of \$180 is due. Please charge my Deposit Account 50-1407 for this fee, as well as any additional fees due.

This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

01/08/2007 JADDO1 00000016 501407 10676079
01 FC:1806 180.00 DA
Respectfully submitted,

Martin D. Moynihan
Registration No. 40,338

Dated: January 2, 2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/676,079
Filing Date	May 1, 1998
First Named Inventor	PECKER Iris et al
Art Unit	1644
Examiner Name	DIBRINO, MARIANNE NMN

Sheet	1	of	4	Attorney Docket Number	26871
-------	---	----	---	------------------------	-------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-6,230,151	08-8-2001	Agrawal et al.	
	2	US-5,799,311	08-25-1998	Agrawal et al.	
	3	US-6,314,420	06-6-2001	Lang et al.	
	4	US-4,937,747	06-26-1990	Koller	
	5	US-6,307,965	10-23-2001	Aggarwal et al.	
	6	US-6,226,792	01-1-2001	Goiffon et al.	
	7	US-5,859,929	01-12-1999	Zhou et al.	
	8	US-5,799,276	08-25-1998	Komissarchik et al.	
	9	US-2002/0068061	06-6-2002	Peretz et al.	
	10	US-5,360,735	01-1-1994	Weinshank et al.	
	11	US-2002/0088019	04-4-2002	Yacoby-Zeevi	
	12	US-5,589,604	12-31-1996	Drohan et al.	
	13	US-5,700,671	12-23-1997	Prieto et al.	
	14	US-5,714,345	03-3-1998	Clark	
	15	US-5,716,817	02-10-1998	T?rnell	
	16	US-6,140,552	10-31-2000	Deboer et al.	
	17	US-2003/0163836	08-28-2003	Garofalo et al.	
	18	US-2002/0194625	12-19-2002	Zcharia et al.	
	19	US-6,190,875	02-20-2001	Ben-Artzi et al.	
	20	US-2001/0006630	05-5-2001	Yacobi-Zeevi et al.	
	21	US-2002/0114801	08-22-2002	Pecker et al.	
	22	US-6,475,763	05-5-2002	Ayal-Hershkovitz et al.	
	23	US-6,426,209	07-30-2002	Ayal-Hershkovitz et al.	
	24	US-6,800,441	05-5-2004	Pecker et al.	
	25	US-2002/0168749	11-14-2002	Pecker et al.	
	26	US-2003/0068806	04-10-2003	Ayal-Hershkovitz et al.	
	27	US-6,946,131	09-20-2005	Peretz et al.	
	28	US-2003/0181687	09-25-2003	Peretz et al.	
	29	US-6,960,471	01-1-2005	Pecker et al.	
	30	US-2003/0190737	09-9-2003	Pecker et al.	
	31	US-2003/0170860	09-11-2003	Pecker et al.	
	32	US-2003/0217375	11-20-2003	Zcharia et al.	
	33	US-2004/0213789	10-28-2004	Yacobi-Zeevi et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	2	of	4	Attorney Docket Number	26871
U.S. PATENT DOCUMENTS					
	34	US-2004/0146497	07-29-2004	Ilan et al.	
	35	US-6,986,996	01-17-2006	Pecker et al.	
	36	US-2004/0146925	07-29-2004	Pecker et al.	
	37	US-2005/0260187	11-24-2005	Ilan et al.	
	38	US-2006/0008892	01-12-2006	Yacobi-Zeevi et al.	
	39	US-2003/0031660	02-13-2003	Yacobi-Zeevi et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
40	PCT WO 00/03036		01-20-2000	Ben-Artzi et al.	
41	PCT WO 00/25817		05-11-2000	Peretz et al.	
42	PCT WO 92/01003		01-23-1992	Nicolson et al.	
43	PCT WO 02/32283		04-25-2002	Yacoby-Zeevi	
44	PCT WO 02/19962		03-14-2002	Ilan et al.	
45	AU 735116		06-28-2001	Pecker et al.	
46	AU 768820		08-8-2004	Ben-Artzi et al.	
47	PCT WO 2004/108065		12-16-2004	Yacobi-Zeevi et al.	
48	PCT WO 99/18852		04-22-1999	Arenson	
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

				Complete if Known	
				Application Number	10/676,079
				Filing Date	May 1, 1998
				First Named Inventor	PECKER Iris et al
				Group Art Unit	1644
				Examiner Name	DIBRINO, MARIANNE NMN
Sheet	3	Of	4	Attorney Docket Number	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	49	Miyake et al. "Highly Specific and Sensitive Detection of Malignancy in Urine Samples From Patients With Urothelial Cancer by CD44v8-10/CD44v10 Competitive RT-PCR", Int. J. Cancer, 79(6): 560-564, 1998. Abstract.			
	50	Marra et al. ""The WashU-HHMI Mouse EST Project", Database EMBL, Accession No. A1122034, XP 002198426, 1998. Abstract.			
	51	Zcharia et al. "Heparanase Regulates Murine Hair Growth", American Journal of Pathology, 166(4): 999-1008, 2005.			
	52	Zhu et al. "Development of Heritable Melanoma in Transgenic Mice", The Journal of Investigative Dermatology, 110: 247-252, 1998.			
	53	Duff "Transgenic Mice Overexpressing Presenilin cDNAs: Phenotype and Utility in the Modeling of Alzheimer's Disease", Central Nervous System Diseases, P.123-128, 2000. Abstract.			
	54	Doetschman "Interpretation of Phenotype in Genetically Engineered Mice", Laboratory Animal Science, 49(2): 137-143, 1999.			
	55	Wall "Transgenic Livestock: Progress and Prospects for the Future", Theriogenology, 45: 57-68, 1996.			
	56	Mullins et al. "Fulminant Hypertension in Transgenic Rats Harboring the Mouse Ren-2 Gene", Nature, 344: 541-544, 1990.			
	57	Hammer et al. "Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human ??m: An Animal Model of HLA-B27-Associated Human Disorders", Cell, 63: 1099-1112, 1990.			
	58	Taurog et al. "HLA-B27 in Inbred and Non-Inbred Transgenic Mice", The Journal of Immunology, 141(11): 4020-4023, 1988.			
	59	Pearce et al. "Development of Glucose Intolerance in Male Transgenic Mice Overexpressing Human Glycogen Synthase Kinase-3? on A Muscle-Specific Promoter", Metabolism, 53(10): 1322-1330, 2004.			
Signature	Considered				

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	4	Of	4	Attorney Docket Number	26871
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
	60	Li et al. "In Vivo Fragmentation of Heparan Sulfate by Heparanase Overexpression Renders Mice Resistant to Amyloid Protein A Amyloidosis", PNAS, 102(18): 6473-6477, 2005.			
	61	Zcharia et al. "Heparanase Accelerates Wound Angiogenesis and Wound Healing in Mouse and Rat Models", The FASEB Journal, 19: 211-221, 2005.			
	62	Zcharia et al. "Molecular Properties and Involvement of Heparanase in Cancer Progression and Mammary Gland Morphogenesis", Journal of Mammary Gland Biology and Neoplasia, 6(3): 311-322, 2001.			
	63	Nadir et al. "Co- Interaction and Increased Release of Tissue Factor Pathway Inhibitor by Heparanase", Blood, 106(11/Part 2): 90B, 2005. Abstract# 4038.			
	64	Spiegel et al. "Heparanase Facilitates Development and SDF-1 Induced Migration of Hematopoietic Stem and Progenitor Cells", Blood, 102(11): 825a-826a, 2003. Abstract# 3056.			
	65	Zcharia et al. "Transgenic Expression of Mammalian Heparanase Uncovers Physiological Functions of Heparan Sulfate in Tissue Morphogenesis, Vascularization, and Feeding Behavior", The FASEB Journal, 18: 252-263, 2004.			
	66	Nasser et al. "Heparanase Neutralizes the Anticoagulation Properties of Heparin and Low-Molecular-Weight Heparin", Journal of Thrombosis and Haemostasis, 4: 560-565, 2006.			
	67	Mullins et al. "Expression of the DBA/2J Ren-2 Gene in the Adrenal Gland of Transgenic Mice", The EMBO Journal, 8(13): 4065-4072, 1989.			
	68	McKenzie et al. "Biochemical Characterization of the Active Heterodimer Form of Human Heparanase (Hpa1) Protein Expressed in Insect Cells", Biochemical Journal, 373: 423-435, 2003.			
	69	Nakajima "Heparanases and Tumor Metastasis", Tanpakushitsu Kakusan Koso, 37(11): 1753-1758, 1992. Abstract.			
	70	Ricoveri et al. "Heparan Sulfate Endoglycosidase and Metastatic Potential in Murine Fibrosarcoma and Melanoma", Cancer Research, 46(8): 3855-3861, 1986. Abstract.			
	71	Hatano et al. "Biologic Activities of Antibodies to the Neutral-Polysaccharide Component of the Pseudomonas Aeruginosa Lipopolysaccharide Are Blocked by O Side Chains and Mucoid Exopolysaccharide (Alginate)", Infect. Immun., 63(1): 21-26.			
	72	Vernet et al. "Virulence Factors (Aerobactin and Mucoid Phenotype) in Klebsiella Pneumoniae and Escherichia Coli Blood Culture Isolates", FEMS Microbiol. Lett., 130(1): 51-57, 1995. Abstract.			
	73	Elkin et al. "Heparanase as Mediator of Angiogenesis: Mode of Action", The FASEB Journal, 15: 1661-1663, 2001.			
	74	Cheng et al. "Increased Sulfation of Glycoconjugates NY Cultured Nasal Epithelia Cells From Patients With Cystic Fibrosis", Journal of Clinical Investigation, 84(1): 68-72, 1989. Abstract.			
Signature				Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.